KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to -$94.9 million.

  • Nektar Therapeutics' Cash from Investing Activities fell 30572.69% to -$94.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.6 million, marking a year-over-year decrease of 4120.15%. This contributed to the annual value of $142.6 million for FY2024, which is 215.39% up from last year.
  • According to the latest figures from Q3 2025, Nektar Therapeutics' Cash from Investing Activities is -$94.9 million, which was down 30572.69% from $49.6 million recorded in Q2 2025.
  • In the past 5 years, Nektar Therapeutics' Cash from Investing Activities registered a high of $130.3 million during Q1 2022, and its lowest value of -$94.9 million during Q3 2025.
  • For the 5-year period, Nektar Therapeutics' Cash from Investing Activities averaged around $44.7 million, with its median value being $43.7 million (2025).
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first surged by 1352108.43% in 2022, then plummeted by 30572.69% in 2025.
  • Nektar Therapeutics' Cash from Investing Activities (Quarter) stood at $120.2 million in 2021, then crashed by 66.71% to $40.0 million in 2022, then plummeted by 56.56% to $17.4 million in 2023, then soared by 246.4% to $60.2 million in 2024, then tumbled by 257.56% to -$94.9 million in 2025.
  • Its Cash from Investing Activities stands at -$94.9 million for Q3 2025, versus $49.6 million for Q2 2025 and $43.7 million for Q1 2025.